CytomX Therapeutics (CTMX) EBITDA (2016 - 2025)
Historic EBITDA for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$14.2 million.
- CytomX Therapeutics' EBITDA fell 34494.81% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year increase of 10155.03%. This contributed to the annual value of $31.8 million for FY2024, which is 667045.45% up from last year.
- Per CytomX Therapeutics' latest filing, its EBITDA stood at -$14.2 million for Q3 2025, which was down 34494.81% from -$120000.0 recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' EBITDA ranged from a high of $23.5 million in Q1 2025 and a low of -$35.1 million during Q4 2021
- Its 5-year average for EBITDA is -$9.2 million, with a median of -$6.5 million in 2024.
- Over the last 5 years, CytomX Therapeutics' EBITDA had its largest YoY gain of 179577.89% in 2024, and its largest YoY loss of 50556.59% in 2024.
- CytomX Therapeutics' EBITDA (Quarter) stood at -$35.1 million in 2021, then soared by 77.3% to -$8.0 million in 2022, then skyrocketed by 112.48% to $995000.0 in 2023, then surged by 1795.78% to $18.9 million in 2024, then crashed by 175.06% to -$14.2 million in 2025.
- Its EBITDA stands at -$14.2 million for Q3 2025, versus -$120000.0 for Q2 2025 and $23.5 million for Q1 2025.